Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Friday, November 13, 2026
In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover two large heart drug trials that lowered markers but not events. They break down Lp(a)HORIZON, which tested pelacarsen, and ZEUS, which tested ziltivekimab. They explain why moving a risk marker is not the same as changing outcomes. Plus: they also discuss an FDA investigation into tumors after the SMA gene therapy Zolgensma, what monitoring may mean for practice, an NFL star's scary neck injury, and more.
Coverage Timeline:
(00:00) This Week’s Headlines (01:44) Pelacarsen: Big Drop, No Benefit (03:03) ZEUS Falls Flat (05:24) Gene Therapy’s Tumor Risk (08:05) Plasma Hack, AI Prior Auth & Statin Nudges (09:45) Jack Campbell’s Recovery
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com.
Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources
